Japan
Updated
Reviewed by Vidhi Upadhyay
Japan Compounded Weight Loss Medications Market Industry Trends and Forecast to 2034: Segmented by (Drug, Channel, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034
Japan · 2024–2034 · placeholder estimates
Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.
China at $151.5 Mn.
India at 15.3% a year.Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.
$236.8 Mn total, 2026–2034
| Year | Market size | Change that year | Since 2025 |
|---|---|---|---|
| 2024 (estimate) | $105.9 Mn | — | — |
| 2025 (base) | $119.6 Mn | +$13.7 Mn | — |
| 2026 (forecast) | $135.0 Mn | +$15.4 Mn | +12.9% |
| 2027 (forecast) | $152.4 Mn | +$17.4 Mn | +27.5% |
| 2028 (forecast) | $172.1 Mn | +$19.7 Mn | +43.9% |
| 2029 (forecast) | $194.3 Mn | +$22.2 Mn | +62.5% |
| 2030 (forecast) | $219.3 Mn | +$25.1 Mn | +83.4% |
| 2031 (forecast) | $247.6 Mn | +$28.3 Mn | +107.1% |
| 2032 (forecast) | $279.5 Mn | +$31.9 Mn | +133.8% |
| 2033 (forecast) | $315.6 Mn | +$36.1 Mn | +164% |
| 2034 (forecast) | $356.3 Mn | +$40.7 Mn | +198% |
Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.
US
$819.7 Mn
China
$151.5 Mn
Canada
$144.4 Mn
Japan (this report)
$119.6 Mn
Germany
$68.9 Mn
UK
$49.9 Mn
France
$46.2 Mn
Brazil
$41.6 Mn
Italy
$38.5 Mn
Spain
$34.9 Mn
Saudi Arabia
$35.2 Mn
Ecuador
$34.0 Mn
India
$29.1 Mn
Mexico
$22.7 Mn
Australia
$21.6 Mn
Russia
$19.0 Mn
New Zealand
$15.4 Mn
South Africa
$12.8 Mn
UAE
$9.9 Mn
Egypt
$5.7 Mn
Philippines
$3.7 Mn
Hong Kong
$2.7 Mn
Malaysia
$2.5 Mn
Singapore
$2.3 Mn
Thailand
$1.9 Mn
Kenya
$1.2 Mn
| Market size, 2025 | $119.6 Mn placeholder estimate |
|---|---|
| Forecast, 2034 | $356.3 Mn placeholder estimate |
| Growth (CAGR), 2025–2034 | 12.9% placeholder estimate |
| Years | 2024 historical · 2025 base year · 2026–2034 forecast |
| Segments | Drug, channel and end user (see all) |
| Key players | Hims & Hers Health, Ro, Empower Pharmacy, Noom, WeightWatchers (see all) |
| Regulator in Japan | PMDASource: Pharmaceuticals and Medical Devices Agency. Checked 14 Nov 2026. |
| Formats | PDF, PPTX, XLSX |
Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.
Compounded weight loss medications are pharmacy-prepared versions of weight-loss drugs, made for individual patients, often during shortages of branded products.
Key segments of the compounded Weight Loss Medications market include drug (Compounded Semaglutide, Compounded Tirzepatide and Others) and channel (Compounding Pharmacies, Telehealth Platforms and Clinics).
Rising rates of obesity and type 2 diabetes, strong clinical results for new weight-loss medicines and growing acceptance of obesity as a chronic disease are driving the compounded Weight Loss Medications market. Wider insurance coverage and more doctors trained in obesity care are adding to demand.
Oral formulations, combination therapies and use in heart, kidney and liver disease open new growth paths for the compounded Weight Loss Medications market, especially in fast-growing emerging economies.
High treatment prices, limited reimbursement, supply shortages and side effects that lead some patients to stop treatment hold back the compounded Weight Loss Medications market. Long-term safety data and lifestyle support are still needed for many patients.
The compounded Weight Loss Medications market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.
Drugs are reviewed by the Pharmaceuticals and Medical Devices Agency (PMDA) and approved by the Ministry of Health, Labour and Welfare (MHLW).[1] Everyone is covered by public health insurance, and the Ministry of Health, Labour and Welfare sets the official price list for covered medicines (NHI prices).[2] Obesity (adults): 5.9% of adults in 2024, the latest WHO figure for Japan.[3]
[1] Pharmaceuticals and Medical Devices Agency. Checked 14 Nov 2026.
[2] Ministry of Health, Labour and Welfare. Checked 14 Nov 2026.
[3] WHO Global Health Observatory, Obesity (adults) (% of adults). Retrieved 15 Nov 2026.
Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for compounded Weight Loss Medications. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in Japan.
What doctors and scientists are doing in Compounded Weight Loss Medications right now, from free public sources.
5.9 % of adults
Obesity (adults), Japan, 2024 (WHO).
Compare every country on the Public Health DashboardSources: PubMed (US National Library of Medicine), ClinicalTrials.gov, WHO Global Health Observatory, World Bank. Fetched 15 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.
[1] WHO Global Health Observatory, Obesity (adults) (% of adults). Retrieved 15 Nov 2026.
[2] World Bank Open Data, Health spending per person (US$ per person). Retrieved 14 Nov 2026.
[3] World Bank Open Data, Doctors (per 1,000 people). Retrieved 14 Nov 2026.
From our blog
Japan · 1 shared keyword
Japan · 1 shared keyword
Japan · 1 shared keyword
Japan · 1 shared keyword
Japan · 1 shared keyword
Japan · 1 shared keyword
Medical Devices · Japan
Medical Devices · Japan
Medical Devices · Japan
Medical Devices · Japan
Healthcare Services · Japan
Digital Health · Japan